- Details
- Badrinath Konety presents Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Blue light cystoscopy (BLC) using hexaminolevulinate HCL (Cysview®) has been previously shown to improve the detection of non-muscle-invasive bladder cancer (NMIBC). The objective of this study was to evaluate the detection of malignant lesions in a heterogenou...
|
- Details
- Diane Newman discusses with Jean Wyman her review of data from the OptumLabs® Data Warehouse and calculated annual incidence for acute and recurrent urinary tract infections (UTIs) in females over 15 years of age. Biographies: Jean F. Wyman, PhD, RN, APRN, GNP-BC, FAAN, FGSA, Professor and Cora Meidl Siehl Chair in Nursing Research, School of Nursing, Center for Aging Science and Care Innovation,...
|
- Details
- Dan George and Megan McNamara discuss the details of a project focused on prostate cancer disparities in the VA health system, leading to her 2018 PCF Young Investigator Award. This work builds upon the Abi Race trial and includes the PANTHER cohort focused on genomic data specific to the African American population. Part two of the project is an extension of the Moonshot Initiative where the VA h...
|
- Details
- Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision. Biographies: Zachary Klaassen, MD, MSc, Urolo...
|
- Details
- (Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...
|
- Details
- Tom Keane provides a comprehensive review of phase 2 KEYNOTE-057, assessing treatment with pembrolizumab for high-risk, non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette (BCG), current standard of care in this patient population. Biography: Thomas E. Keane, MBBCh, FRCSI, FACS Related Content: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMI...
|
- Details
- Monty Pal and Jaime Landman discuss the value of collaboration with multiple disciplines to effectively manage patients diagnosed with kidney cancer. They provide a historical overview of the treatment of kidney cancer bringing the conversation to revolutionary advances, adding their view on the impact of survival in this patient population. Biographies: Jaime Landman, M.D. Chair of the Department...
|
- Details
- (Length of Discussion: 12 min) Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progressi...
|
- Details
- (Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data...
|
- Details
- Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biographies: Michael Hofman, MBBS (Hon...
|
